Oncolytic adenovirus

Further information: Oncolytic virus

Adenovirus varieties have been explored extensively as a viral vector for gene therapy and also as an oncolytic virus.[1]

Of the many different viruses being explored for oncolytic potential, an adenovirus was the first to be approved by a regulatory agency, the genetically modified H101 strain. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer.[2][3]

  1. ^ Harrington KJ, Pandha H, Vile RG, eds. (2008). Viral therapy of cancer. Chichester, England ; Hoboken, NJ: John Wiley & Sons. pp. 1–13. ISBN 978-0-470-01922-1. OCLC 183831087.
  2. ^ Frew SE, Sammut SM, Shore AF, Ramjist JK, Al-Bader S, Rezaie R, Daar AS, Singer PA (2008). "Chinese health biotech and the billion-patient market". Nature Biotechnology. 26 (1): 37–53. doi:10.1038/nbt0108-37. PMC 7096943. PMID 18183014.
  3. ^ Garber K (2006). "China Approves World's First Oncolytic Virus Therapy for Cancer Treatment". JNCI Journal of the National Cancer Institute. 98 (5): 298–300. doi:10.1093/jnci/djj111. PMID 16507823.